Primecap Management Co. CA Sells 44,959 Shares of BioNTech SE Sponsored ADR $BNTX

Primecap Management Co. CA cut its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 1.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,001,466 shares of the company’s stock after selling 44,959 shares during the quarter. Primecap Management Co. CA owned about 1.66% of BioNTech worth $426,036,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise purchased a new stake in shares of BioNTech during the first quarter valued at $36,000. LRI Investments LLC increased its stake in shares of BioNTech by 234.6% in the 2nd quarter. LRI Investments LLC now owns 445 shares of the company’s stock worth $47,000 after purchasing an additional 312 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in BioNTech by 472.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock worth $61,000 after purchasing an additional 472 shares during the period. Banque Transatlantique SA purchased a new position in BioNTech during the first quarter valued at $80,000. Finally, Costello Asset Management INC bought a new stake in BioNTech during the first quarter valued at about $91,000. Institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on BNTX shares. Cowen restated a “hold” rating on shares of BioNTech in a research note on Monday, November 3rd. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a report on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Tuesday, October 14th. UBS Group lifted their price objective on shares of BioNTech from $115.00 to $117.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. Finally, JPMorgan Chase & Co. cut their price objective on BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a research report on Thursday, October 23rd. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus price target of $135.20.

BioNTech Stock Down 0.1%

Shares of BNTX stock opened at $102.53 on Wednesday. The stock has a market cap of $24.65 billion, a P/E ratio of -64.08 and a beta of 1.54. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average of $102.92 and a 200 day moving average of $104.94. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $129.27.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business had revenue of $1.78 billion for the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter last year, the business earned $0.81 EPS. The company’s quarterly revenue was up 22.0% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.